Department of Medical Oncology, National Cancer Center Hospital, Chuo-ku, Japan,
Department of Medical Oncology, National Cancer Center Hospital, Chuo-ku, Japan.
Oncology. 2022;100(7):370-375. doi: 10.1159/000524500. Epub 2022 Apr 11.
Synovial sarcoma (SS) predominantly affects adolescents and young adults. Doxorubicin with or without ifosfamide therapy is the standard first-line treatment for unresectable or metastatic SS. However, there is no standard second-line chemotherapy regimen. The purpose of the current study was to evaluate the outcomes of second-line chemotherapy for patients with SS.
We retrospectively evaluated the outcomes of 61 patients with unresectable or metastatic SS who had received first-line chemotherapy at our institution between 1997 and 2017. Patients who received second-line chemotherapy were included in the analysis. Outcomes of the chemotherapy were evaluated.
Among the 61 patients treated with first-line chemotherapy, we identified 32 patients who received second-line chemotherapy. Most patients (62.5%) were under 40 years of age. Regarding second-line chemotherapy regimens, 6 (18.8%) patients were treated with doxorubicin with/without ifosfamide, 6 (18.8%) with ifosfamide and etoposide, 4 (12.5%) with docetaxel and gemcitabine, 5 (15.6%) with pazopanib, 2 (6.2%) with trabectedin, and 1 (3.1%) with eribulin. The overall response rate according to the Response Evaluation Criteria in Solid Tumors for all patients was 9.4%. Eleven patients (34.3%) achieved disease-control for >6 months. The median follow-up duration was 15.2 months. The 1-year progression-free and overall survival rates were 33.1% and 67.1%, respectively.
Our exploratory study revealed that the response rate of second-line chemotherapy regimens for patients with SS was 9.4%. Therefore, there is an urgent need to develop more active therapeutic regimens for SSs.
滑膜肉瘤（SS）主要影响青少年和年轻成年人。多柔比星联合或不联合异环磷酰胺治疗是不可切除或转移性 SS 的标准一线治疗方法。然而，目前还没有标准的二线化疗方案。本研究的目的是评估二线化疗治疗 SS 患者的结果。
我们回顾性评估了 1997 年至 2017 年期间在我院接受一线化疗的 61 例不可切除或转移性 SS 患者的二线化疗结果。接受二线化疗的患者被纳入分析。评估了化疗的结果。
在接受一线化疗的 61 例患者中，我们确定了 32 例接受二线化疗的患者。大多数患者（62.5%）年龄在 40 岁以下。关于二线化疗方案，6 例（18.8%）患者接受多柔比星联合/不联合异环磷酰胺治疗，6 例（18.8%）患者接受异环磷酰胺和依托泊苷治疗，4 例（12.5%）患者接受多西他赛和吉西他滨治疗，5 例（15.6%）患者接受帕唑帕尼治疗，2 例（6.2%）患者接受托泊替康治疗，1 例（3.1%）患者接受艾瑞布林治疗。根据实体瘤反应评估标准，所有患者的总体缓解率为 9.4%。11 例患者（34.3%）疾病控制时间>6 个月。中位随访时间为 15.2 个月。1 年无进展生存率和总生存率分别为 33.1%和 67.1%。
我们的探索性研究表明，二线化疗方案治疗 SS 患者的缓解率为 9.4%。因此，迫切需要为 SS 开发更有效的治疗方案。
